Description
Fascaplysin (114719-57-2) is a novel marine natural product isolated fromThorectandra sp.1A potent and selective inhibitor of cyclin dependent kinase 4/cyclin D1 (IC50= 0.35 μM) and is less selective for Cdk6/D1 (IC50= 3.4 μM). Displays antiangiogenic acitivity.2Fascaplysin displays high cytotoxic activity against small cell lung cancer cell lines acting via multiple mechanisms including topoisomerase I, DNA integrity and ROS.3
References
[1] RAJEEV SONI. Inhibition of Cyclin-Dependent Kinase 4 (Cdk4) by Fascaplysin, a Marine Natural Product[J]. Biochemical and biophysical research communications, 2000, 275 3: Pages 877-884. DOI:
10.1006/bbrc.2000.3349[2] JING LIN Hai M C Xiao Jun Yan. Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo.[J]. Cancer Chemotherapy and Pharmacology, 2007, 59 4: 439-445. DOI:
10.1007/s00280-006-0282-x[3] HAMILTON G. Cytotoxic effects of fascaplysin against small cell lung cancer cell lines.[J]. Marine Drugs, 2014: 1377-1389. DOI:
10.3390/md12031377
